Cargando…
Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Sarcomas are a rare malignancy of mesenchymal tissues, comprizing a plethora of unique subtypes, with more than 60 types. The sheer heterogeneity of disease phenotype makes this a particularly difficult cancer to treat. Radiotherapy, chemotherapy and surgery have been employed for over three decades...
Autores principales: | Birdi, Harsimrat Kaur, Jirovec, Anna, Cortés-Kaplan, Serena, Werier, Joel, Nessim, Carolyn, Diallo, Jean-Simon, Ardolino, Michele |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7852926/ https://www.ncbi.nlm.nih.gov/pubmed/33526607 http://dx.doi.org/10.1136/jitc-2020-001580 |
Ejemplares similares
-
Oncolytic Rhabdovirus Vaccine Boosts Chimeric Anti-DEC205 Priming for Effective Cancer Immunotherapy
por: Tzelepis, Fanny, et al.
Publicado: (2020) -
Correction: Immunotherapy for sarcomas: new frontiers and unveiled opportunities
Publicado: (2022) -
Sarcoma Immunotherapy: Confronting Present Hurdles and Unveiling Upcoming Opportunities
por: Jeong, Sehan, et al.
Publicado: (2023) -
Retroperitoneal Sarcoma Care in 2021
por: Schmitz, Erika, et al.
Publicado: (2022) -
The strategic combination of trastuzumab emtansine with oncolytic rhabdoviruses leads to therapeutic synergy
por: Arulanandam, Rozanne, et al.
Publicado: (2020)